Skip to main content
Top
Published in: Diabetologia 8/2014

01-08-2014 | Article

Aberrant gut microbiota composition at the onset of type 1 diabetes in young children

Authors: Marcus C. de Goffau, Susana Fuentes, Bartholomeus van den Bogert, Hanna Honkanen, Willem M. de Vos, Gjalt W. Welling, Heikki Hyöty, Hermie J. M. Harmsen

Published in: Diabetologia | Issue 8/2014

Login to get access

Abstract

Aims/hypothesis

Recent studies indicate that an aberrant gut microbiota is associated with the development of type 1 diabetes, yet little is known about the microbiota in children who have diabetes at an early age. To this end, the microbiota of children aged 1–5 years with new-onset type 1 diabetes was compared with the microbiota of age-matched healthy controls.

Methods

A deep global analysis of the gut microbiota composition was established by phylogenetic microarray analysis using a Human Intestinal Tract Chip (HITChip).

Results

Principal component analyses highlighted the importance of age when comparing age-matched pairs. In pairs younger than 2.9 years, the combined abundance of the class Bacilli (notably streptococci) and the phylum Bacteroidetes was higher in diabetic children, whereas the combined abundance of members of Clostridium clusters IV and XIVa was higher in the healthy controls. Controls older than 2.9 years were characterised by a higher fraction of butyrate-producing species within Clostridium clusters IV and XIVa than was seen in the corresponding diabetic children or in children from the younger age groups, while the diabetic children older than 2.9 years could be differentiated by having an increased microbial diversity.

Conclusions/interpretation

The results from both age groups suggest that non-diabetic children have a more balanced microbiota in which butyrate-producing species appear to hold a pivotal position.
Appendix
Available only for authorised users
Literature
1.
go back to reference Borody TJ, Khoruts A (2012) Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9:88–96CrossRef Borody TJ, Khoruts A (2012) Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9:88–96CrossRef
2.
go back to reference de Vos WM, de Vos EA (2012) Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 70(Suppl 1):S45–S56PubMedCrossRef de Vos WM, de Vos EA (2012) Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 70(Suppl 1):S45–S56PubMedCrossRef
3.
go back to reference Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489:220–230PubMedCentralPubMedCrossRef Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489:220–230PubMedCentralPubMedCrossRef
7.
go back to reference Sokol H, Pigneur B, Watterlot L et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736PubMedCentralPubMedCrossRef Sokol H, Pigneur B, Watterlot L et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736PubMedCentralPubMedCrossRef
8.
go back to reference Brugman S, Klatter FA, Visser JT et al (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49:2105–2108PubMedCrossRef Brugman S, Klatter FA, Visser JT et al (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49:2105–2108PubMedCrossRef
9.
11.
go back to reference de Goffau MC, Luopajarvi K, Knip M et al (2013) Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes 62:1238–1244PubMedCentralPubMedCrossRef de Goffau MC, Luopajarvi K, Knip M et al (2013) Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes 62:1238–1244PubMedCentralPubMedCrossRef
12.
go back to reference Murri M, Leiva I, Gomez-Zumaquero JM et al (2013) Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med 11:46PubMedCentralPubMedCrossRef Murri M, Leiva I, Gomez-Zumaquero JM et al (2013) Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med 11:46PubMedCentralPubMedCrossRef
13.
go back to reference Mejía-León ME, Petrosino JF, Ajami NJ, Domínguez-Bello MG, de la Barca AM (2014) Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep 4:3814PubMedCentralPubMedCrossRef Mejía-León ME, Petrosino JF, Ajami NJ, Domínguez-Bello MG, de la Barca AM (2014) Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep 4:3814PubMedCentralPubMedCrossRef
14.
go back to reference Vaarala O, Atkinson MA, Neu J (2008) The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57:2555–2562PubMedCentralPubMedCrossRef Vaarala O, Atkinson MA, Neu J (2008) The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57:2555–2562PubMedCentralPubMedCrossRef
15.
go back to reference Brown CT, Richardson AG, Giongo A et al (2011) Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 6:e25792PubMedCentralPubMedCrossRef Brown CT, Richardson AG, Giongo A et al (2011) Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 6:e25792PubMedCentralPubMedCrossRef
16.
go back to reference Van Immerseel F, Ducatelle R, de Vos M et al (2010) Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol 59:141–143PubMedCrossRef Van Immerseel F, Ducatelle R, de Vos M et al (2010) Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol 59:141–143PubMedCrossRef
17.
go back to reference Flint HJ, Duncan H, Scott KP, Louis P (2007) Interactions and competition within the microbial community of the human colon: links between diet and health. Environ Microbiol 9:1101–1111PubMedCrossRef Flint HJ, Duncan H, Scott KP, Louis P (2007) Interactions and competition within the microbial community of the human colon: links between diet and health. Environ Microbiol 9:1101–1111PubMedCrossRef
18.
go back to reference Segain JP, de la Raingeard BD, Bourreille A et al (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut 47:397–403PubMedCentralPubMedCrossRef Segain JP, de la Raingeard BD, Bourreille A et al (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut 47:397–403PubMedCentralPubMedCrossRef
19.
go back to reference Furet JP, Kong LC, Tap J et al (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:3049–3057PubMedCentralPubMedCrossRef Furet JP, Kong LC, Tap J et al (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:3049–3057PubMedCentralPubMedCrossRef
20.
go back to reference Onkamo P, Vaananen S, Karvonen M, Tuomilehto J (1999) Worldwide increase in incidence of type I diabetes—the analysis of the data on published incidence trends. Diabetologia 42:1395–1403PubMedCrossRef Onkamo P, Vaananen S, Karvonen M, Tuomilehto J (1999) Worldwide increase in incidence of type I diabetes—the analysis of the data on published incidence trends. Diabetologia 42:1395–1403PubMedCrossRef
21.
go back to reference Karvonen M, Pitkaniemi J, Tuomilehto J (1999) The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 22:1066–1070PubMedCrossRef Karvonen M, Pitkaniemi J, Tuomilehto J (1999) The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 22:1066–1070PubMedCrossRef
22.
go back to reference Weets I, de Leeuw I, Du Caju MV et al (2002) The incidence of type 1 diabetes in the age group 0–39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 25:840–846PubMedCrossRef Weets I, de Leeuw I, Du Caju MV et al (2002) The incidence of type 1 diabetes in the age group 0–39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 25:840–846PubMedCrossRef
23.
go back to reference Pundziute-Lycka A, Dahlquist G, Nystrom L et al (2002) The incidence of type I diabetes has not increased but shifted to a younger age at diagnosis in the 0–34 years group in Sweden 1983–1998. Diabetologia 45:783–791PubMedCrossRef Pundziute-Lycka A, Dahlquist G, Nystrom L et al (2002) The incidence of type I diabetes has not increased but shifted to a younger age at diagnosis in the 0–34 years group in Sweden 1983–1998. Diabetologia 45:783–791PubMedCrossRef
24.
go back to reference Rajilic-Stojanovic M, Heilig HG, Molenaar D et al (2009) Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ Microbiol 11:1736–1751PubMedCentralPubMedCrossRef Rajilic-Stojanovic M, Heilig HG, Molenaar D et al (2009) Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ Microbiol 11:1736–1751PubMedCentralPubMedCrossRef
25.
go back to reference Yu Z, Morrison M (2004) Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques 36:808–812PubMed Yu Z, Morrison M (2004) Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques 36:808–812PubMed
26.
go back to reference Jalanka-Tuovinen J, Salonen A, Nikkila J et al (2011) Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One 6:e23035PubMedCentralPubMedCrossRef Jalanka-Tuovinen J, Salonen A, Nikkila J et al (2011) Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One 6:e23035PubMedCentralPubMedCrossRef
27.
go back to reference Lous P, Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294:1–8CrossRef Lous P, Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294:1–8CrossRef
28.
go back to reference Koenig JE, Spor A, Scalfone N et al (2011) Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 108(Suppl 1):4578–4585PubMedCentralPubMedCrossRef Koenig JE, Spor A, Scalfone N et al (2011) Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 108(Suppl 1):4578–4585PubMedCentralPubMedCrossRef
29.
go back to reference Yatsunenko T, Rey FE, Manary MJ et al (2012) Human gut microbiome viewed across age and geography. Nature 486:222–227PubMedCentralPubMed Yatsunenko T, Rey FE, Manary MJ et al (2012) Human gut microbiome viewed across age and geography. Nature 486:222–227PubMedCentralPubMed
30.
go back to reference Hague A, Butt AJ, Paraskeva C (1996) The role of butyrate in human colonic epithelial cells: an energy source or inducer of differentiation and apoptosis? Proc Nutr Soc 55:937–943PubMedCrossRef Hague A, Butt AJ, Paraskeva C (1996) The role of butyrate in human colonic epithelial cells: an energy source or inducer of differentiation and apoptosis? Proc Nutr Soc 55:937–943PubMedCrossRef
31.
go back to reference Peng L, Li ZR, Green RS, Holzman IR, Lin J (2009) Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139:1619–1625PubMedCentralPubMedCrossRef Peng L, Li ZR, Green RS, Holzman IR, Lin J (2009) Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139:1619–1625PubMedCentralPubMedCrossRef
32.
go back to reference Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM (2010) Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 16:1138–1148PubMedCrossRef Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM (2010) Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 16:1138–1148PubMedCrossRef
33.
go back to reference Russo I, Luciani A, de Cicco P, Troncone E, Ciacci C (2012) Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn’s mucosa through modulation of antioxidant defense machinery. PLoS One 7:e32841PubMedCentralPubMedCrossRef Russo I, Luciani A, de Cicco P, Troncone E, Ciacci C (2012) Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn’s mucosa through modulation of antioxidant defense machinery. PLoS One 7:e32841PubMedCentralPubMedCrossRef
34.
go back to reference Joshi N, Caputo GM, Weitekamp MR, Karchmer AW (1999) Infections in patients with diabetes mellitus. N Engl J Med 341:1906–1912PubMedCrossRef Joshi N, Caputo GM, Weitekamp MR, Karchmer AW (1999) Infections in patients with diabetes mellitus. N Engl J Med 341:1906–1912PubMedCrossRef
35.
go back to reference Nowakowska M, Jarosz-Chobot P (2004) Streptococcus group B (GBS)—characteristic, occurrence in children and adolescents with type 1 diabetes mellitus. Pol J Microbiol 53:17–22PubMed Nowakowska M, Jarosz-Chobot P (2004) Streptococcus group B (GBS)—characteristic, occurrence in children and adolescents with type 1 diabetes mellitus. Pol J Microbiol 53:17–22PubMed
36.
go back to reference García E, López R (1995) Streptococcus pneumoniae type 3 encodes a protein highly similar to the human glutamate decarboxylase (GAD65). FEMS Microbiol Lett 133:113–119PubMedCrossRef García E, López R (1995) Streptococcus pneumoniae type 3 encodes a protein highly similar to the human glutamate decarboxylase (GAD65). FEMS Microbiol Lett 133:113–119PubMedCrossRef
37.
go back to reference Soyucen E, Gulcan A, Aktuglu-Zeybek AC, Onal H, Kiykim E, Aydin A (2013) Differences in the gut microbiota of healthy children and those with type 1 diabetes. Pediatr Int. doi:10.1111/ped.12243 Soyucen E, Gulcan A, Aktuglu-Zeybek AC, Onal H, Kiykim E, Aydin A (2013) Differences in the gut microbiota of healthy children and those with type 1 diabetes. Pediatr Int. doi:10.​1111/​ped.​12243
38.
go back to reference Collins MD, Lawson PA, Willems A et al (1994) The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol 44:812–826PubMedCrossRef Collins MD, Lawson PA, Willems A et al (1994) The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol 44:812–826PubMedCrossRef
39.
go back to reference Johnson JL, Francis BS (1975) Taxonomy of the Clostridia: ribosomal ribonucleic acid homologies among the species. J Gen Microbiol 88:229–244PubMedCrossRef Johnson JL, Francis BS (1975) Taxonomy of the Clostridia: ribosomal ribonucleic acid homologies among the species. J Gen Microbiol 88:229–244PubMedCrossRef
40.
41.
go back to reference Lauber CL, Zhou N, Gordon JI, Knight R, Fierer N (2010) Effect of storage conditions on the assessment of bacterial community structure in soil and human-associated samples. FEMS Microbiol Lett 307:80–86PubMedCentralPubMedCrossRef Lauber CL, Zhou N, Gordon JI, Knight R, Fierer N (2010) Effect of storage conditions on the assessment of bacterial community structure in soil and human-associated samples. FEMS Microbiol Lett 307:80–86PubMedCentralPubMedCrossRef
42.
go back to reference Nyman M (2000) Fermentation and bulking capacity of indigestible carbohydrates: the case of inulin and oligofructose. Br J Nutr 87(Suppl 2):S163–S168 Nyman M (2000) Fermentation and bulking capacity of indigestible carbohydrates: the case of inulin and oligofructose. Br J Nutr 87(Suppl 2):S163–S168
Metadata
Title
Aberrant gut microbiota composition at the onset of type 1 diabetes in young children
Authors
Marcus C. de Goffau
Susana Fuentes
Bartholomeus van den Bogert
Hanna Honkanen
Willem M. de Vos
Gjalt W. Welling
Heikki Hyöty
Hermie J. M. Harmsen
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 8/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3274-0

Other articles of this Issue 8/2014

Diabetologia 8/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.